New ACC updates: a US trial is recruiting, plus two key papers on treatment options.
Here is what is new for adrenocortical carcinoma patients and caregivers.
🧪 Cabozantinib and Cemiplimab Trial
A Phase 2 trial run by the National Cancer Institute is currently recruiting in the US.
It tests adding cabozantinib (a drug that blocks cancer cell growth signals) to cemiplimab (an immunotherapy that helps your immune system attack tumors).
Sites include Memorial Sloan Kettering Cancer Center, Mayo Clinic in Rochester, and other US centers.
📄 Adjuvant Therapy Review
A new review summarizes evidence for adjuvant mitotane, platinum-based chemotherapy, and radiation after surgery.
It highlights how doctors use risk stratification to choose the best follow-up care for each patient.
🩺 Embolization Experience
A single-center paper describes using transarterial embolization (blocking blood flow to shrink tumors) for ACC.
This approach was used both before surgery and for palliative care when surgery is not an option.
#AdrenocorticalCarcinoma #CancerResearch #ACC #PatientSupport
AI-generated; for informational purposes only, not medical advice